


Biochemistry of Cancer

Tumor Suppressor Genes



displaced normal retina
retinoblastoma
Figure 7.1 The Biology of Cancer © Garland Science 2014

Table 7.1 Examples of human tumor suppressor genes that have been cloned

| Name of gene | Chromosomal location | Familial cancer syndrome | Sporadic cancer | Function of gene product |
|------------------------------|----------------------|--------------------------------------|--|---|
| <i>SDHB</i> | 1p36.1 | paraganglioma | — | succinate dehydrogenase |
| <i>CHD5</i> | 1p36.31 | cutaneous melanoma | many types | histone reader, transcriptional inducer |
| <i>HRPT2</i> | 1q25-32 | parathyroid tumors, jaw fibromas | parathyroid tumors | chromatin protein |
| <i>FH</i> | 1q42.3 | familial leiomyomatosis ^a | — | fumarate hydratase |
| <i>FHIT</i> | 3p14.2 | — | many types | diadenosine triphosphate hydrolase |
| <i>BAP1</i> | 3p21.1 | mesothelioma, melanoma | mesothelioma, uveal melanoma | ubiquitin hydrolase |
| <i>RASSF1A</i> | 3p21.3 | — | many types | multiple functions |
| <i>TGFBR2</i> | 3p2.2 | HNPCC | colon, gastric, pancreatic carcinomas | TGF- β receptor |
| <i>VHL</i> | 3p25-26 | von Hippel-Lindau syndrome | renal cell carcinoma | ubiquitylation of HIF |
| <i>hCDC4</i> | 4q32 | — | endometrial carcinoma | ubiquitin ligase |
| <i>APC</i> | 5q21-22 | familial adenomatous polyposis coli | colorectal, pancreatic, and stomach carcinomas; prostate carcinoma | β -catenin degradation |
| <i>NKX3.1</i> | 8p21.2 | — | prostate carcinoma | homeobox TF |
| <i>miR-124a^b</i> | 8p23.1 | — | many types | suppresses CDK6 |
| <i>p16^{INK4a} c</i> | 9p21 | familial melanoma | many types | CDK inhibitor |
| <i>p14^{ARF} d</i> | 9p21 | — | all types | p53 stabilizer |

Table 7.1 Examples of human tumor suppressor genes that have been cloned

| Name of gene | Chromosomal location | Familial cancer syndrome | Sporadic cancer | Function of gene product |
|-----------------------------------|----------------------|--|--|---|
| <i>PTC</i> | 9q22.3 | nevroid basal cell carcinoma syndrome | medulloblastomas | receptor for hedgehog GF |
| <i>let 7a (miRNA)^a</i> | 9q22.32 | — | many types | suppresses Ras, Myc |
| <i>TSC1</i> | 9q34 | tuberous sclerosis | — | inhibitor of mTOR ^f |
| <i>BMPRI</i> | 10q21-22 | juvenile polyposis | — | BMP receptor |
| <i>ANXA7</i> | 10q21 | — | breast, prostate, stomach | endocytosis |
| <i>PTEN^g</i> | 10q23.3 | Cowden's disease, breast and gastrointestinal carcinomas | glioblastoma; prostate, breast, and thyroid carcinomas | PIP ₃ phosphatase |
| <i>WT1</i> | 11p13.5-6 | Wilms tumor | Wilms tumor | TF |
| <i>MEN1</i> | 11p13 | multiple endocrine neoplasia | — | histone modification, transcriptional repressor |
| <i>BWS/CDKN1C</i> | 11p15.5 | Beckwith-Wiedemann syndrome | — | p57 ^{KIP2} CDK inhibitor |
| <i>SDHD^h</i> | 11q23.1 | paraganglioma, pheochromocytoma | pheochromocytoma | mitochondrial protein |
| <i>CBL</i> | 11q23.3 | juvenile myelomonocytic leukemia | adult myelomonocytic leukemia | SH2-containing ubiquitin ligase |
| <i>RB</i> | 13q14.2 | retinoblastoma, osteosarcoma | retinoblastoma; sarcomas; bladder, breast, esophageal, and lung carcinomas | transcriptional repressor; control of E2Fs |
| <i>miR-15a/16-1</i> | 13q14.3 | — | B-cell lymphoma | suppresses Bcl-2, Mcl-1, cyclin D1, Wnt3a |

Table 7.1 Examples of human tumor suppressor genes that have been cloned


| Name of gene | Chromosomal location | Familial cancer syndrome | Sporadic cancer | Function of gene product |
|-------------------------|----------------------|--------------------------------------|------------------------------------|-------------------------------|
| <i>RUNX1</i> | 21q22.12 | familial platelet disorder | AML | TF |
| <i>SMF3ⁱ</i> | 22q11.2 | rhabdoid predisposition syndrome | malignant rhabdoid tumors | chromosome remodeling |
| <i>NF2</i> | 22q12.2 | neurofibroma-predisposition syndrome | schwannoma, meningioma, ependymoma | cytoskeleton-membrane linkage |
| <i>WTX</i> | Xq11.1 | — | Wilms tumor | β -catenin degradation |

^aFamilial leiomyomatosis includes multiple fibroids, cutaneous leiomyomas, and renal cell carcinoma. The gene product is a component of the tricarboxylic cycle.
^bmiR124a-1 genes are also located at 8q12.3 and 20q13.331.
^cAlso known as MTS1, CDKN2, and p16.
^dThe human homolog of the murine p19^{INK4} gene.
^eThese are altogether 11 loci encoding let7 miRNAs in the human genome.
^fmTOR is a serine/threonine kinase that controls, among other processes, the rate of translation and activation of Akt/PKB, TSC1 (hamartin), and TSC2 (tuberin), thereby controlling both cell size and cell proliferation.
^gAlso called hRAC or TEP1.
^hSDHD encodes subunit D of the succinate dehydrogenase (succinate-ubiquinone oxidoreductase) enzyme, a component of the mitochondrial respiratory chain complex II.
ⁱThe CBP gene is involved in chromosomal translocations associated with AML. These translocations may reveal a role of a segment of CBP as an oncogene rather than a tumor suppressor gene.
^jAlso termed Carney complex.
^kEncodes the Smad4 TF associated with TGF- β signaling; also known as MAD4 and SMAD4.
^lThe human SRSF5 protein is a component of the large SRSF complex that is responsible for remodeling chromatin in a way that leads to transcriptional repression through the actions of histone deacetylases. The rhabdoid predisposition syndrome involves susceptibility to atypical teratoid/rhabdoid tumors, choroid plexus carcinoma, medulloblastomas, and extracranial rhabdoid tumors.
 Adapted in part from E.R. Fearon, Science 278:1043-1050, 1997; and in part from D.J. Marsh and R.T. Zou, Cancer Lett. 181:125-164, 2002.
 Table 7.1 (part 4 of 6): The Biology of Cancer © Garland Science 2014


Tumor Suppressor Genes

- Recessive phenotype
 - Oncogenes (viral or cellular) dominate a phenotype – i.e. activation of cancer like behaviors. Ras, Myc, Erb – all stimulate aggressive growth, motility, invasion, migration and tumor growth
 - These are dominant cancer phenotypes
 - First hint of a different sort of cancer gene came with fusogenic experiments using PEG or specific virus

• NIH 3T3 and monkey kidney cells fused with proteins expressed by Sendai virus



Fusion Expt



- Hybrid cells – heterokaryons eventually only one set (mixed) of chromosomes will remain
- Tumor cells (expected dominant allele) did not appear
- Indicating another gene/allele was involved. Loss of which was only way to detect. Thus recessive.. Sort of...

Figure 7.14 The Biology of Cancer (© Garland Science 2014)






Figure 7.2 The Biology of Cancer (© Garland Science 2014)

Simple Definition

- Tumor suppressor gene (aka anti-oncogene) stops cell growth protecting cell from cancer like behavior
 - Act in recessive behavior giving rise to the “two hit” hypothesis. Loss of both genes must take place before phenomenon is observed.
 - Retinoblastoma is a classic example of tumor suppressor genes
 - Some tumor suppressor genes are not recessive but “dominant negative” Mutation of one gene copy will prevent normal function. Typically a dimer were mutation allows dimer to form with wild-type protein but block its effect– p53 is an example

Retinoblasoma

- Tumor arising in youth very rare – 1 in 20,000. Occurs early. Tumor within the eye causing blindness.
- Most treatment by radiation or removal of the eye



- Two forms.
 - Those with no family history (unilateral) have tumors in one eye and is considered sporadic. No further risk of other tumors later
 - Familial form (bilateral) often have tumors in both eyes and have greater risk of other tumors forming at distal sites

non-retinal tumors of retinoblastoma patients




Figure 7.4a The Biology of Cancer (© Garland Science 2014)

Kinetics of age and frequency

- Suggest unilateral result from a single event while sporadic tumors require two random mutations/events.
- Lead to speculation of an unknown gene called Rb.




Figure 7.5 The Biology of Cancer (© Garland Science 2014)






Figure 7.6 The Biology of Cancer (© Garland Science 2014)

Rb function



- Retinoblastoma – RB1 gene expressing pRB.
- Phosphorylated transcription REPRESSOR that blocks Go-G1 transition.
- Binds and blocks E2F TF which drives DNA replication. E2F is target of several oncogenes



Loss of Heterozygosity (LOH)

- Several tumor suppressors display LOH
- Removal of remaining TS gene by recombination events during mitosis
- Small genetic population interbreeding (endogamy) leads to LOH




Figure 2.7 The Biology of Cancer (© Garland Science 2014)

Other mechanisms of TS loss

- Hypermethylation of cytosine bases.
- CpG (C is methylated following a G base) such CpG islands occur in some **promoter regions**
- CH₃-cytosine represses TF and Promoter binding but is reversible.
- Mechanism (not the enzyme, but control of methylation) is largely unclear at this time.
- 70% of genes have CpG islands.




Figure 2.15 The Biology of Cancer (© Garland Science 2014)




Table 7.2 Examples of hypermethylated genes found in human tumor cell genomes

| Name of gene | Nature of protein function | Type of tumor |
|-----------------------------|---|-----------------------------------|
| RAR β | nuclear receptor for differentiation | breast, lung |
| p53 ^{R175} | CDK inhibitor | gastric, pancreatic, hepatic, AML |
| TIMP3 | inhibitor of metalloproteinases | diverse tumors |
| IGFBP | sequesters IGF-1 factor | diverse tumors |
| CDKN2A/p16 ^{INK4A} | inhibitor of CDK4/6 | diverse tumors |
| CDKN2B/p15 ^{INK4B} | inhibitor of CDK4/6 | diverse tumors |
| p14 ^{ARF} | inhibitor of HDM2/MDM2 | colon, lymphoma |
| APC | inducer of β -catenin degradation | colon carcinomas |
| ER | estrogen receptor | breast |
| p73 | aids p53 to trigger apoptosis | diverse tumors |
| GSTP1 | mutagen inactivator | breast, liver, prostate |
| MGMT | DNA repair enzyme | colorectal |
| CDH1 | cell-cell adhesion receptor | bladder, breast, colon, gastric |
| DKK1 | Wnt inhibitor | colon |
| DAPK | kinase involved in cell death | bladder |
| MLH1 | DNA mismatch repair enzyme | colon, endometrial, gastric |
| PTEN | degrades PIP ₃ | diverse tumors |
| TGFBR2 | TGF- β receptor | colon, gastric, small-cell lung |
| THBS1 | angiogenesis inhibitor | colon, glioblastoma |
| VHL | ubiquitin ligase | kidney, hemangioblastoma |
| RB | cell cycle regulator | retinoblastoma |
| CASP8 | apoptotic caspase | neuroblastoma, SCLC |
| APAF1 | pro-apoptotic cascade | melanoma |
| CTMP | inhibitor of AK/PKB | glioblastoma multiforme |


Adapted in part from C. A. Eads et al. *Cancer Res.* 61:3410–3418, 2001, and M. Esteller. *Nat. Rev. Cancer* 8:286–298, 2007.

TS Genes APC – Colon Cancer

- Colon cancers – longest part of the intestine. Most are secreting mucus cell cancers (adenocarcinomas)
- Often combined with rectal cancer (last several inches of intestine) for colorectal cancer
- Most CR cancers show no or little familial association ~5% are familial adenomatous polyposis (FAP)

APC Familial Adenomatous Polyposis

- Those with family history with parent or sibling with disease has nearly a three fold greater risk of colorectal cancer. Less than 1% of CR Cancer have FAP
- FAP patients display a carpet of polyps



Your Colon

- Colonic crypt cells provide new cells as stem cells at the bottom of the deep "cave" divide – retaining one daughter stem cell and a second daughter cell that is differentiated
- Differentiated cells migrate to luminal surface (epithelial cells) of the colon to secrete mucus and serve as the lining of the gut
- Most cells die within 3-4 days.
- Cells at surface face harsh environment of mutagenic compounds from diet, radicals from oxidation and other harsh typical conditions of intestine (pH ect...)
- Mutagens occur often in these cells but quickly die before progressing to cancer cells – **thus only cancers that can happen will stop the out-migration of epithelial cells where additional lesions can induce proliferation and tumor formation can take place... APC**

- Crypts – shown with white arrowhead
- Epithelial cells migrate through small hole at the top of crypt (narrow black arrow)
- Broad white arrow points to protruding daughter cells

Wnt, catenin, APC & cancer

Wild-type

- Stromal cells (fibroblasts, inflammatory cells and endothelial cells) secrete growth factors, cytokines and other agonists including Wnt, to induce cell growth.
- The paracrine stromal cell signaling activates Wnt signaling in dividing stem and differentiated cells
- Wnt increases β -catenin and decreases APC protein
- β -catenin binds TF Tcf/Lef leading to increased proliferation and decreased differentiation (more stem cell like)
- APC – causes the degradation of β -catenin
- Luminal cells are not stimulated by stromal cells, less Wnt, \rightarrow less β -catenin and more APC (which also decreases β -catenin). Leading to loss of proliferation (cell cycle) and more differentiated (less stem cell/cancer like) behavior and cell death

Cancer

- Tumor suppressor APC mutations do not reduce β -catenin slowing migration and causing greater proliferation and less differentiation. Allow build up of additional mutations for full development of tumor mass – multiple polyps

Wnt and β -catenin Signaling

- β -catenin has several signaling roles – one is via Wnt
- Wnt – extracellular GPCR 350-400 aa agonist. Family of conserved glycoproteins that are also palmitoylated for secretion and membrane association
- Wnt binds to GPCR class (Fz/frizzled family receptors) AND must bind to co-receptor lipoprotein-related protein (LRP). TOGETHER, Wnt signals in two distinct pathways – Canonical and noncanonical

Wnt and β -catenin Signaling

Table 1: Wnt- and β -catenin pathway genes that are involved in diseases and syndromes

| Gene | Condition/disease | Mutation or activity/ expression change | Reference |
|------------------|---------------------------|---|-----------|
| WNT1 | Schizophrenia | Exon 3 | 24 |
| WNT3 | Tuberculosis | LOF | 13 |
| WNT4 | Hemera | LOF | 14 |
| WNT2 | Kidney damage | Exon 2 | 16,17 |
| WNT4 | Polycystic kidney disease | Variable | 18 |
| WNT5a | Leukemia | LOF, reduced | 21 |
| WNT5a | Melanoma | Overexpt | 22 |
| WDR33 | Osteoarthritis | SNP, reduced | 28 |
| PCP4 | FEAR | LOF | 30 |
| LRP5 | FRAX, low bone mass | LOF | 34,42 |
| LRP6 | High bone mass | LOF | 37,38 |
| DKK1/4 | Lung cancer | Overexpt | 47 |
| APC | Cancer | LOF | 48 |
| ARM1 | Cancer | LOF | 45 |
| ARM2 | Cancer, tooth agenesis | LOF | 53 |
| β -catenin | Cancer | LOF | 45 |
| β -catenin | Aggressive thrombosis | Overexpt | 61 |
| β -catenin | Pulmonary fibrosis | Overexpt | 65 |

APC: adenomatous polyposis coli; DKK1/4: Dickkopf 1/4; LRP5/6: low density lipoprotein receptor family 5/6; Frizzled 1/2: frizzled 1/2 gene function; LRP: low density lipoprotein receptor; WNT: wnt; GSK3: glycogen synthase kinase 3; CK1: casein kinase 1; PPSA: prostatic specific antigen; TCF: transcription factor 1/4; TCF/LEF: transcription factor 1/4/lymphoid enhancing factor 1/4; Axin: axin; Dishevelled: dishevelled; Axin complex: axin complex; Axin complex assembly: axin complex assembly; Axin complex disassembly: axin complex disassembly; GSK3/CK1: glycogen synthase kinase 3/casein kinase 1; PPI1: protein phosphatase 1; β -catenin: beta-catenin; Wnt: wnt; LRP: low density lipoprotein receptor; Frizzled: frizzled; Dishevelled: dishevelled; Axin: axin; Wtx: wntless; Apc: adenomatous polyposis coli; β -catenin: beta-catenin; degradation: degradation; nuclear membrane: nuclear membrane; Groucho: groucho; Tcf/Lef: transcription factor 1/4/lymphoid enhancing factor 1/4.

- β -catenin is phosphorylated and targeted for proteolysis in the absence of Wnt
- ... or in the absence of Wnt, β -catenin is not phosphorylated and remains intact and binds to TF factors
- GSK3B phosphorylation of β -catenin targets b-cat for ubiquitination and ultimately proteolysis
- Half life of β -catenin is about 20 min – w/ phosphorylation; 1-2 hours after phosphorylation. Thus unless GSK3B action is blocked there will be very little β -catenin in cytoplasm
- Together Wnt signaling and β -Catenin are involved in a large number of cell regulation events and loss of control leads to many diseases/disorders
- APC in polyps, high Wnt signaling in several breast cancers

Canonical Wnt Signaling vs Non-canonical Wnt Signaling

In biochemistry, a pathway or signaling method that is thought to be general and understood is considered canonical (i.e. GPCR signaling pathway).

- Wnt signaling is much more important than cancer – but is our focus here
- Canonical pathway – lack of wnt leads to loss of β -cat
- Canonical Wnt signaling remains without LRP phosphorylation (most GSK3 and some Casein kinase 1 (CK1))
- Frizzled (Fz) is a GPCR activates Dishevelled (Dsh) which is also capable of being phosphorylated
- Axin is a scaffolding protein (also another tumor suppressor) coordinates binding of kinases, small G protein regulators, β -cat and ubiquitin ligase (for β -cat degradation).
- GSK & CK1 phosphorylate Axin and APC \rightarrow tighter binding of Axin and APC with β -catenin leading to more β -cat phosphorylation and degradation
- Wtx/Wlms tumor suppressor gene on X chromosome role is unclear
- APC role is complicated in both signaling pathways

APC

- Adenomatous polyposis coli gene – tumor suppressor protein encoded by APC gene.
- Large protein that complexes with axin and conductin to bring β -catenin to GSK3B and CK1.
- APC forms oligomers, an armadillo region (ARM - small repeats forming hairpin turns and helices) and binding sites for other proteins.
- Dimers of APC are critical for APC function. APC mutants can bind and block wild-type APC (dominant tumor suppressor function)
- APC forms multiprotein complex to phosphorylate β -catenin.
- In Wnt activated crypt cells – APC is not expressed leaving β -catenin undegraded for TF binding/activation

Partners competing for the binding site on the ARM domain

- E-cadherin (cell adhesion): Cadherin repeats, Axinin binding motif, Membrane-spanning receptor
- Axin (scaffold/degradation): GSK3 kinase binding motif, DIX domain, Axinin binding motif, DIX domain
- APC (scaffold/degradation): Axinin binding motif, Axinin binding motif, Axinin binding motif
- TCF/LEF (transcription): Transactivator motifs, ARM low affinity binding motif, Axinin binding motif, GSK3 binding motif

